1		Genome-wide multi-trait analysis of irritable bowel syndrome and
2		related mental conditions identifies 38 new genetic hits
3		
4	Si	lvia Alemany* <sup>1-3</sup> , María Soler Artigas <sup>1-4</sup> , Judit Cabana <sup>1-3</sup> , Dana Salim Fakhreddine <sup>1</sup> , Natalia
5	Ll	onga <sup>1-2</sup> , Laura Vilar-Ribó <sup>1-3</sup> , Amanda Rodríguez-Urrutia <sup>1-3,5</sup> , Judit Palacio <sup>2</sup> , Ana María
6	Go	onzález-Castro <sup>6</sup> , Beatriz Lobo <sup>6-8</sup> , Carmen Alonso-Cotoner <sup>6-9</sup> , Magnus Simrén <sup>10-11</sup> , Javier
7	Sa	ntos <sup>6-9</sup> , Josep Antoni Ramos-Quiroga <sup>1-3,5</sup> , Marta Ribasés <sup>*1-4</sup> .
8		
9	1.	Psychiatric Genetics Unit, Group of Psychiatry Mental Health and Addiction, Vall d'Hebron
10		Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain.
11	2.	Department of Mental health, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
12	3.	Biomedical Network Research Centre on Mental Health (CIBERSAM), Instituto de Salud
13		Carlos III, Madrid, Spain.
14	4.	Department of Genetics, Microbiology, and Statistics, Faculty of Biology, Universitat de
15		Barcelona, Barcelona, Spain.
16	5.	Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona,
17		Barcelona, Spain
18	6.	Laboratory of Neuro-Immuno-Gastroenterology, Digestive System Research Unit, Vall
19		d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Barcelona,
20		Spain.
21	7.	Department of Gastroenterology, Vall d'Hebron Hospital Universitari, Vall d'Hebron
22		Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
23	8.	Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
24	9.	Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
25		(CIBERHED), Instituto de Salud Carlos III, Madrid, Spain.
26	10.	Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska
27		Academy, University of Gothenburg, Gothenburg, Sweden.

- 28 11. Centre for Functional GI and Motility Disorders, University of North Carolina, Chapel Hill,
- 29 North Carolina, USA.
- 30
- 31 \*Corresponding authors: Marta Ribasés and Silvia Alemany.
- 32 Psychiatric Genetics Unit, Group of Psychiatry Mental Health and Addiction, Vall d'Hebron
- 33 Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona Spain. Passeig Vall
- d'Hebron, 119-129, 08035 Barcelona, Spain Phone: +34 934894162. marta.ribases@vhir.org;
- 35 <u>silvia.alemany@vhir.org</u>.

# 36 ABSTRACT

37 Background: Irritable bowel syndrome (IBS) is a chronic disorder of gut-brain 38 interaction frequently accompanied by mental conditions, including depression and 39 anxiety. Despite showing substantial heritability and being partly determined by a 40 genetic component, the genetic underpinnings explaining the high rates of comorbidity 41 remain largely unclear and there are no conclusive data on the temporal relationship 42 between them. Exploring the overlapping genetic architecture between IBS and mental 43 conditions may help to identify novel genetic loci and biological mechanisms 44 underlying IBS and causal relationships between them.

45 Methods: We quantified the genetic overlap between IBS, neuroticism, depression and 46 anxiety, conducted a multi-trait genome-wide association study (GWAS) considering 47 these traits and investigated causal relationships between them by using the largest 48 GWAS to date.

49 **Results:** IBS showed to be a highly polygenic disorder with extensive genetic sharing 50 with mental conditions. Multi-trait analysis of IBS and neuroticism, depression and 51 anxiety identified 42 genome-wide significant hits for IBS, of which 38 are novel. Fine-52 mapping risk loci highlighted 289 genes upregulated during early embryonic brain 53 development and gene-sets related with psychiatric, digestive and autoimmune 54 disorders. IBS-associated genes were enriched for target genes of anti-inflammatory and 55 antirheumatic drugs, anesthetics and opioid dependence pharmacological treatment. 56 Mendelian-randomization analysis accounting for correlated pleiotropy identified 57 bidirectional causal effects between IBS and neuroticism and depression and causal 58 effects of the genetic liability of IBS on anxiety.

59 Conclusions: These findings provide evidence of the polygenic architecture of IBS,
60 identify novel hits for IBS and extend previous knowledge on the genetic overlap and
61 relationship between gastrointestinal and mental disorders.

- 62 Keywords: Irritable bowel syndrome (IBS), neuroticism, depression, anxiety, multi-
- 63 trait genome-wide association study (MTAG)

# 65 INTRODUCTION

Irritable bowel syndrome (IBS) is one of the most prevalent disorders of gut-brain interaction with a population lifetime risk of 11%<sup>1</sup> and a point prevalence of 4.1% according to the strict Rome IV criteria<sup>2</sup>. IBS research is extremely challenging due to the multifactorial etiology of the disease and the heterogeneity of patients, who present high comorbidity rates for mental disorders, particularly, anxiety and depression, which impacts negatively on the patients' quality of life<sup>1,3,4</sup>.

72

73 A recent systematic review revealed that the prevalence of anxiety and depression symptoms among IBS patients is 39.1% and 28.8%, respectively <sup>5</sup>. In addition, IBS has 74 75 been associated with more severe depressive symptoms compared to healthy controls 76 and, when co-existing with psychiatric disorders, gastrointestinal symptoms are more severe and disabling  $^{6-11}$ . This close association between IBS, anxiety and depression is 77 78 also supported by neuroimaging studies and might be related to the bi-directional 79 communication between the brain and the digestive system, termed the brain-gut-axis, 80 which occurs through microbiota, neural, neuroimmune and neuroendocrine pathways 12-14. This idea agrees with evidence indicating that psychiatric interventions, including 81 82 antidepressants or cognitive-behavioral therapy, improve IBS patients functioning and 83 suggests that common pathophysiological mechanisms may be underlying these conditions<sup>15</sup>. 84

85

IBS, anxiety and depression are partly determined by a genetic component and show
substantial heritability ranging from 6% for IBS to 30%-50% for anxiety and depression
<sup>16-18</sup>. The largest GWAS on IBS conducted to date included 53,400 cases and 433,201
controls and identified six genome-wide significant loci <sup>18</sup> which represents an

90 improvement over the previous study identifying four independent hits <sup>19</sup>. Interestingly, 91 among 173 traits, three mental conditions (neuroticism, depression and anxiety) were 92 the most genetically correlated traits with IBS <sup>18</sup>. Despite these strong genetic 93 correlations, the genetic underpinnings explaining the high rates of comorbidity 94 between IBS and mental conditions remain largely unclear and there are no conclusive 95 data on the temporal and causal relationship between them <sup>18,19</sup>.

96

97 In the present study we investigated the shared genetic architecture and the nature of the 98 relationship between IBS and three highly genetically correlated conditions 99 (neuroticism, depression and anxiety) using summary statistics of the largest GWAS 100 datasets available so far by (i) estimating the genetic correlation and overlap between 101 them, (ii) conducting a Multi-Trait Analysis of GWAS (MTAG) to identify novel 102 genetic loci for IBS and (iii) performing downstream analyses to explore the overlaping 103 genetic basis with other disorders and traits as well as causal relationships between 104 them.

105

# 106 MATERIALS AND METHODS

108 We used publicly available SNP-level GWAS summary statistics for IBS <sup>18</sup>, 109 neuroticism <sup>20</sup>, depression <sup>21</sup> and anxiety (Table 1). For further details see 110 Supplementary Note 1.

111

# 112 SNP-based heritability genetic correlation and overlap

113 SNP heritability  $(h^2_{SNP})$  and pair-wise genetic correlation between IBS and each mental 114 condition was calculated using linkage disequilibrium score regression (LDSC) analysis

<sup>107</sup> Samples

115 <sup>22</sup>. Conversion of  $h^2_{\text{SNP}}$  estimates from observed to liability scale was done using a 116 population prevalence of 11%, 25%, 30% and 14% for IBS, neuroticism, depression 117 and anxiety, respectively. Polygenic overlap between IBS and each mental condition was quantified using MiXeR<sup>23</sup>. MiXeR caclulates the number of trait-influencing loci 118 119 for each trait (univariate model) and for both traits (bivariate model) and the proportion 120 of variants with concordant direction of effects for both traits. The proportion of SNPs 121 shared by two traits is indicated by the Dice coefficient. Model fit was assessed using 122 the Akaike Information Criterion (AIC). For further details see Supplementary Note 2.

123

# 124 Multi-Trait Analysis of GWAS (MTAG)

125 To identify new loci for IBS, SNP-level GWAS for IBS, neuroticism, depression and anxiety were meta-analyzed using MTAG<sup>24</sup>. To discard inflation in our results we 126 127 calculated the max-false discovery rate (max-FDR) using the default settings as previously described <sup>24,25</sup>. Independent lead SNPs from MTAG-IBS results (*P*-value<5-128 E08) were identified through clumping (r2=0.05, kb=5000) using the 1000 Genomes 129 130 Project Phase 3 European reference panel (http://www.internationalgenome.org/) and PLINK1.09 as described by Eijsbouts et al.<sup>18</sup>. We carried out conditional analyses to 131 132 evaluate independence between secondary (within 5000kb and  $r^{2}<0.2$ ) and index 133 variants within each locus using COJO implemented in Genome-wide Complex Trait Analysis (GCTA)<sup>26</sup>. For further details on conditional analysis see Supplementary Note 134 135 3.

136

## 137 Credible variants and functional annotation

Sets of credible variants (credible-sets) were identified by fine-mapping the independent
 lead SNPs of MTAG-IBS using three different tools , FINEMAP 1.3.1 <sup>27</sup>, PAINTOR

140 v3.0 <sup>28</sup> and CAVIARBF v.0.2.1 <sup>29</sup> following the pipeline available elsewhere <sup>30</sup>.
141 Variants located in a region of 5000 kb around the lead SNPs were included in the
142 analysis and we assumed that there was only one causal variant per locus. We used the
143 recommended parameters of each tool and only variants identified by all three methods
144 were considered.\_Functional annotation of the credible variants was conducted using
145 FUMA<sup>31</sup>. For further details see Supplementary Note 4.

146

# 147 Gene-based and gene-set analyses of MTAG-IBS results

148 Gene-based and gene-set analyses of MTAG-IBS risk loci were performed using MAGMA v1.08<sup>32</sup> implemented in FUMA<sup>31</sup>. Tissue specific gene expression was 149 150 explored using MAGMA gene-property analysis of expression data from GTEx v8 and 151 BrainSpan available in FUMA (databases detailed in Supplementary Note 5). All gene 152 sets were obtained from the Molecular Signatures Database (MSigDB v6.2) and 153 included GO, KEGG, BIOCARTA and Reactome representing a total of 11,960 gene 154 sets. The Bonferroni-corrected significance threshold was 0.05/11960 gene sets=4.18E-155 06.

156

#### 157 **Drug target identification**

To explore whether finemapped genes related with IBS were enriched for target genes of drugs (druggable genes) we performed enrichment analysis based on information from the PharmGKB using WebGestAlt <sup>33</sup>. Identified drugs were classified according to available information from the Anatomical Therapeutic Chemical (ATC) classification system.

### 164 **Partitioned heritability and genetic correlations**

We partitioned  $h^2_{SNP}$  of MTAG-IBS results by functional annotation categories using 165 stratified LDSC <sup>34</sup>. We calculated whether any of the 28 specific genomic categories 166 included in the analysis was enriched for variants that contribute to  $h^2_{SNP}$ . Annotations 167 168 for these functional genomic categories (e.g. coding or regulatory regions) were 169 obtained from LDSC website (https://github.com/bulik/ldsc/wiki/Partitioned-170 Heritability). We focused on categories extended by 500bp in either direction. 171 Enrichment/depletion of heritability in each category is calculated as the proportion of 172 heritability attributable to SNPs in the specified category divided by the proportion of 173 total SNPs annotated to that category. The Bonferroni-corrected significance threshold 174 was 0.05/28 annotations=0.0021.

175

176 We explored genetic correlations between our MTAG-IBS results and gastrointestinal, immunological and psychiatric disorders using LDSC analysis <sup>22</sup>. We selected all 177 178 GWAS summary statistics of gastrointestinal/abdominal, immunological/systemic (UK 179 Biobank: 21 phenotypes) and psychiatric disorders (PGC: 7 phenotypes) available in the MR-Base database (Supplementary Table 14)<sup>35</sup>. We used GWAS summary statistics 180 181 including both males and females of European ancestry. If several GWAS were 182 available for the same disorder, we chose the study with the largest effective sample 183 size (N effective = 4NcaNco/(Nca+Nco)). The Bonferroni-corrected significance 184 threshold used was 0.05/28 traits=0.0018.

185

### 186 Causal analysis using summary effect estimates (CAUSE)

187 Causal relationships between IBS and correlated traits were assessed considering 188 independent variants (r2=0.05; kb=5000) associated with the exposure with P < 1.0E-03

using CAUSE <sup>36</sup>. Bidirectional relationships were tested considering IBS as exposure 189 190 and depression, anxiety or neuroticism as outcomes and vice-versa. Given that SE was 191 not available from the largest study on neuroticism to date 37, we used the GWAS 192 dataset on neuroticism by Luciano et al. in 329,821 subjects as an alternative 38. The 193 strengths of CAUSE involve accounting for correlated horizontal pleiotropic effects (i.e. 194 when a variant affects the outcome and the mediator through shared heritable factors) 195 and using a less stringent significance threshold (P<1.0E-3) allowing the incorporation 196 of more variants to the analyses. CAUSE compares two nested models, a sharing and a 197 causal model. Both models allow for horizontal pleiotropy (correlated pleiotropy (eta)) 198 but only the casual model includes a causal effect parameter (gamma). The sharing and 199 the causal model are compared against a null model and against each other. Model 200 comparisons are carried out using the expected log pointwise posterior density (ELPD), 201 a Bayesian model comparison approach that estimates how well the posterior 202 distributions of a particular model are expected to predict a new set data. When P < 0.05203 the second model fits the data better than the first model. There is evidence of causal 204 effects when the causal model represents a significant improvement in the model fit of 205 the sharing model.

206 For further details see Supplementary Note 9.

207

### 208 **RESULTS**

# 209 SNP-based heritability, genetic correlation and overlap

The latest GWAS on IBS <sup>18</sup>, neuroticism <sup>20</sup>, depression <sup>21</sup> and anxiety used herein are summarized in Table 1 and Supplementary Note 1. The estimated SNP heritability  $(h^2_{\text{SNP}})$  was 6.9% (SE=0.004) for IBS, 14.6% (SE=0.005) for neuroticism, 9.9% (SE=0.004) for depression and 8.3% (SE=0.011) for anxiety (Table 2). We found

214 evidence of strong genetic correlation between IBS and all three mental conditions, 215 ranging from 53% to 68% (Table 2). Univariate MiXeR analysis revealed that IBS and 216 neuroticism were highly polygenic, with around twelve thousand variants explaining 217 90% of SNP heritability (12,438 variants for IBS and 12,308 for neuroticism; 218 Supplementary Table 1a). Bivariate MiXeR analysis showed that the majority of the 219 variants influencing IBS were shared with neuroticism (10,793 (SE=1.094) out of 220 12,438 (SE=1.305) variants, Dice coefficient=0.87), with a high proportion of variants 221 being concordant (71%) (Supplementary Table 1a and Supplementary Figure 1). 222 Unfortunately, MiXeR was unable to accurately quantify the genetic overlap between 223 IBS and depression or anxiety according to the Akaike Information Criterion (AIC; 224 Supplementary Table 1b).

225

# 226 Multi-Trait Analysis of GWAS (MTAG)

227 To identify novel loci for IBS, we combined the summary statistics from the GWAS on 228 IBS, neuroticism, depression and anxiety using MTAG, increasing the estimated 229 effective sample size from 486,601 in the original IBS dataset to 887,490. The max-230 FDR of MTAG-IBS analysis was low (0.020) suggesting no inflation, consistent with 231 the similar mean chi-square values for the different GWAS, ranging from 1.08 for 232 anxiety to 1.69 for neuroticism. After MTAG analysis, the number of genome-wide 233 significant SNPs for IBS increased from six in the original GWAS to 42 independent 234 SNPs in 37 loci in the current study (Figure 1, Supplementary Figure 2, Table 3 and 235 Supplementary Table 2). Comparing these results with the ones originally described for IBS<sup>18</sup>, 38 out of the 42 SNPs identified herein were novel for IBS and all of them 236 237 showed consistent direction of the association (Figure 1a and Supplementary Table 3). 238 Of them, 11 were not previously associated with neuroticism, depression or anxiety

239 (Figure 1d). The remaining signals, 27 in total, were novel risk loci for IBS but 240 previously reported for neuroticism and/or depression (Table 3, Figure 1d) and overall 241 showed consistent direction of association with that reported in the original studies (Figure 1a). Of the six loci previously identified in IBS<sup>18</sup>, four of them, on chromosome 242 243 3, 6, 9 and 11, were among the significant loci for IBS in the current study and the two 244 additional ones, in chromosome 13, showed suggestive evidence of association (P < 5E-245 07; Table 3). Among top findings, we found lead SNPs nearby genes involved in 246 transcriptional regulation, including non-coding RNAs (RP11-629G13.1 and MSH5-247 SAPCD1), RNA splicing (CELF4), chromatin remodeling (EP300 and HIST1H3J), 248 mRNA transport (FAM120A) or nucleic acid binding (TCF4 and ELAVL2), as well as in 249 brain development (TMEM161B) or presynaptic activity (PCLO).

250

### 251 Credible variants and functional annotation

252 We identified a total of 1,818 Bayesian credible variants in the 37 independent loci for 253 IBS (Supplementary Table 4). Their functional annotation revealed over-presentation of 254 SNPs in introns (64.6%), intergenic regions (21.7%) or located in non-coding RNA 255 (9.4%) (Figure 2 and Supplementary Table 5). A total of 75% of the variants within 256 credible sets were located in open chromatin regions (minimum chromatin state  $\leq 7$ ), 257 3% were likely to affect the binding of transcription factors (RegulomeDB scores from 258 1b to 2c) and 0.05% may be deleterious (Combined Annotation Dependent Depletion 259 (CADD) score > 12.37) (Figure 2 and Supplementary Table 5). Forty-eight variants 260 were previously related by GWAS (P < 5E-07) to digestive-related phenotypes (e.g. 261 inflammatory bowel disease, gastroesophageal reflux or gut microbiota relative 262 abundance), lifestyle factors (e.g. alcohol consumption, lifetime smoking, coffee 263 consumption or moderate to vigorous physical activity levels) and brain and

neuropsychiatric phenotypes (e.g. neuroticism, depression, anxiety, cognition or brain morphology) (Supplementary Table 6). In addition, we found that more that half of the credible variants (n=953; 52%) were expression quantitative trait loci (eQTL) for at least one gene in one brain area (n=895; 49%) and/or digestive tissue (n=690; 38%; Supplementary Table 7).

269

270 Credible variants were mapped to 289 unique genes (Supplementary Table 8) that were 271 significantly enriched in genes upregulated during early embryonic brain development 272 (8th post conceptual week; Supplementary Figure 3) and in several gene-sets 273 (Supplementary Table 9). Among the most significant ones, we found psychiatric 274 disorders (GWAS catalog: autism spectrum disorder or schizophrenia, P-275 adjusted=4.96E-193), digestive disorders (GWAS catalog: ulcerative colitis, P-276 adjusted=1.13E-57 and inflammatory bowel disease, *P*-adjusted=7.05E-40), 277 autoimmune disease (KEGG: Systemic lupus erythematosus, *P*-adjusted=7.91E-61) and 278 histone deacetylases (Reactome: HDACS deacetylate histones, P-adjusted=3.09E-46) 279 (Supplementary Table 9).

280

### 281 Gene-based and gene-set analyses of MTAG-IBS risk loci

The gene-based analysis identified 76 significant genes, which were associated with expression changes in the cerebellum (P=5.2E-09), frontal cortex (P=9.8E-07), anterior cingulate cortex (P=1.8E-05), basal ganglia nuclei (nucleus accumbens: P=6.9E-05; caudate: P=9.7E-04) and hypothalamus (P=4.3E-04) (Supplementary Table 10, Supplementary Figure 4) as well as with gene expression during the 21<sup>st</sup> post conceptual week (P=8.5E-04) (Supplementary Figure 5). Among top findings, we found genes with a role in brain development and synaptic function, including *CADM2* and

289 *NCAM1*, previously identified in the latest GWAS on IBS, and also genes involved in 290 transcriptional regulation through mRNA transport or chromatin structure, including 291 *FAM120A*, *PHF2* and different histone coding genes. When we conducted the gene-set 292 analysis we found the *branching morphogenesis of a nerve* pathway significantly 293 associated with IBS (gene-set size=10 genes; P= 1.7E-06) (Supplementary Table 11).

# 294 Drug target identification

The enrichment analysis on druggable genes showed enrichment of MTAG-IBSfinemapped credible genes in druggable genes for 21 drugs (Supplementary Table 12), being 1-lysine (P < 2.2E-16), belinostat (P=8.6E-10), s-adenosylmethionine (P=7.0E-09) and allopurinol (P=1.5E-07), the top ones (Supplementary Table 12). They also included drugs related to musculo-skeletal system, such as anti-inflammatory and antirheumatic drugs, or related to the nervous system, such as anesthetics and drugs used in opioid dependence (Supplementary Table 12).

302

# 303 Partitioned heritability and genetic correlations

When we partitioned the  $h_{SNP}^2$  of IBS, we observed significant heritability enrichment in seven functional categories (Figure 2 and Supplementary Table 13), with the strongest enrichment of variants in conserved regions (enrichment=2.01; *P*=4.0E-09), DNase I hypersensitive sites (DHSs) regions (enrichment=1.66; *P*=9.1E-08) and histone H3 lysine 9 acetylation (H3K9ac) peaks (enrichment=6.88; *P*=1.1E-07).

309

We found significant genetic correlations between IBS and 13 gastrointestinal, immunological or psychiatric disorders using GWAS summary statistics available in the MR-Base database <sup>35</sup>, including gastric reflux (rg=0.51; P=2.6E-36), the cross-disorder

313 GWAS from the PGC involving schizophrenia, bipolar disorder, major depressive 314 disorder, autism spectrum disorders (ASD) and attention-deficit/hyperactivity disorder 315 (ADHD) (rg=0.44, P=9.7E-46), diverticulitis (rg=0.44, P=7.4E-22), hiatus hernia 316 (rg=0.43; P=4.7E-20) and chronic fatigue syndrome (rg=0.39, P=2.0E-04), among 317 others (Figure 2 and Supplementary Table 14). 318 Causal analysis using summary effect estimates (CAUSE) 319 CAUSE <sup>36</sup> showed consistent evidence for a causal effect of the genetic liability of IBS 320 321 on neuroticism ( $\Delta$ ELPD=-3.6, SE=1.9, P=0.031), depression ( $\Delta$ ELPD=-5.9, SE=1.8,

- 322 P=5.4E-03) and anxiety ( $\Delta$ ELPD=-2.9, SE=1.7, P=0.049). We also found evidence for
- 323 reverse causality with a causal effect of the genetic liability of neuroticism and
- 324 depression on IBS ( $\Delta$ ELPD=-7.3, SE=1.4, P=1.5E-07 and  $\Delta$ ELPD=-6.3, SE=1.4,
- 325 P=1.8E-06 respectively) but there was no evidence for a causal relationship when
- 326 anxiety was considered as exposure and IBS as outcome (Figure 2, Supplementary
- 327 Table 15a and 15b and Supplementary Figure 6).
- 328

### 330 **DISCUSSION**

331 In the present study we found extensive genetic sharing between IBS, neuroticism, 332 depression and anxiety, and identified 42 genome-wide significant hits for IBS, of 333 which 38 are novel. Our findings confirm the polygenic architecture of the disorder, with more than 12,000 variants explaining 90% of the  $h^2_{SNP}$  and represent a great 334 advance over the previously reported six genome-wide risk loci<sup>18</sup>. Significant signal 335 336 enrichment was found in genes showing heightened expression in the brain during early 337 embryonic development and playing prominent roles in mental and digestive disorders, 338 autoimmune diseases and transcription regulation.

339

340 Our results confirm a role on IBS of genes involved in brain development and synaptic function as well as genes previously associated with psychiatric conditions <sup>18</sup>. We 341 342 detected 27 loci for IBS also associated with at least one of the three mental conditions 343 under study, and found evidence supporting that IBS and neuroticism, which is genetically correlated with many psychiatric disorders <sup>39</sup>, share a considerable 344 345 proportion of their genetic background. The widespread common genetic risk sharing 346 with mental conditions was further supported by the positive genetic correlation found 347 between IBS and many psychiatric disorders (i.e. schizophrenia, ADHD, autism or 348 depression) and by the IBS associated variants being located within genes significantly 349 expressed in the brain. These results are in agreement with the higher burden of mental 350 disorders often co-existing in IBS patients, add further evidence of substantial 351 pleiotropy of contributing loci and underscore that genetic influences on IBS may 352 transcend diagnostic boundaries.

353

354 Among top findings we identified genes associated with IBS in previous GWAS, such 355 as CADM2 and NCAM1, members of the synaptic cell adhesion molecules that play a role in synapse organization and plasticity <sup>40,41</sup>. Interestingly, NCAM peptide mimetics 356 have been proven to have both antidepressant and anti-inflammatory effects <sup>42,43</sup>, 357 358 pointing them as a potential therapeutic target for IBS. Novel loci for IBS include 359 interesting genes previously associated with depression and other mental disorders, such as *RERE*, that regulates retinoic acid signaling during development <sup>44-46</sup>, *PCLO*, 360 involved in synaptic vesicle trafficking, TMEM161B<sup>47</sup>, a brain-expressed 361 transmembrane protein <sup>48</sup>, *RBFOX1*, a splicing regulator mainly expressed in neurons, 362 that is one of the most pleiotropic genes among psychiatric disorders <sup>49</sup> or DRD2, 363 364 encoding the dopamine receptor D2R and one of the strongest candidates for psychiatric disorders and traits <sup>50</sup>. Interestingly, several studies in animal models suggested an 365 366 important role for dopamine signaling both in the development and progression of inflammatory bowel disease <sup>51</sup> and treatment with D2R agonists decreased the severity 367 of ulcerative colitis in mice and rats <sup>52</sup>. 368

369

370 We also provide new insights underlying IBS, showing strong evidence of 371 transcriptional regulation mechanisms playing a role in the disorder, including non-372 coding RNAs and histone modification. We found genes encoding histones and histone 373 modifying enzymes among top findings, and enrichment of IBS associations in histone 374 acetylation and methylation peaks and in target genes for the histone deacetylase inhibitor belinostat <sup>53</sup>. These findings are in agreement with previous results involving 375 376 chromatin modifications in maintenance of anxiety behavior and nociception and in visceral hypersensitivity induced by early-life stress <sup>54,55</sup>. Additionally, top findings also 377 include non-coding RNAs, an epigenetic mechanism that has been involved in 378

379 regulation of genes related with visceral pain response and intestinal permeability <sup>56-58</sup>.
380 These results add additional evidence towards the role of epigenetic programming in
381 inflammation, visceral pain as well as in intestinal permeability, sensibility and motility
382 in both humans and animal models of IBS <sup>54,55,59,60</sup>.

383

384 Despite many of the findings pointing out neurobiological processes and mental 385 disorders, we also detected links between IBS and gastrointestinal-related phenotypes. 386 Fine mapping showed that 38% of the credible variants were eQTLs for at least one 387 digestive tissue and that credible sets were located in genes enriched in different 388 digestive disorders, including ulcerative colitis and inflammatory bowel disease. In 389 addition, positive genetic correlations were found between IBS and gastric reflux, diverticulitis, hiatus hernia, cholelithiasis/gallstones and gastric/stomach ulcers, among 390 391 others, which adds evidence on the overlap between the genetic risk for IBS and for 392 other digestive-related disorders and traits. These findings may reflect the multi-393 factorial etiology proposed for IBS involving psychological factors, abnormal brain functioning and dysregulation of brain-gut interactions <sup>15,61–63</sup>, as previously proposed in 394 different psychiatric disorders such as depression <sup>64</sup>. 395

396

397 IBS-associated signals were also enriched in target genes of relevant drugs, including l-398 lysine or S-adenosylmethionine. L-lysine acts as partial serotonin 5-HT4 receptor 399 antagonist and inhibits serotonin-mediated intestinal pathologies in rats, including 400 anxiety and stress-induced fecal excretion and severity of diarrhea <sup>65</sup>. Interestingly, l-401 lysine, and other 5-HT4 receptor antagonists, are promising targets for the treatment of 402 diarrhea-predominant IBS <sup>66,67</sup> and may aminorate serotonin disturbances in gut and 403 brain that account for part of intestinal and mental disorders <sup>65</sup>. Additional drugs of

404 interest include S-adenosylmethionine, involved in neurotransmission signaling that has
405 a putative antidepressant effect<sup>68,69</sup> or allopurinol that improves inflammatory bowel
406 disease clinical outcomes <sup>70</sup>, among others.

407

408 Despite the high prevalence of psychiatric comorbidities reported in patients with IBS, 409 particularly anxiety and depression, a clear temporal relationship between them has not 410 been well established. We found evidence for a bidirectional causal effect between IBS 411 and neuroticism or depression when accounting for correlated pleiotropy, which strengthens previous evidence <sup>18</sup>. In addition, we found evidence for a causal effect of 412 413 the genetic liability of IBS on anxiety. These findings support that IBS increases the risk 414 of subsequent depressive and anxiety disorders described in longitudinal study designs <sup>71</sup> and also previous evidence supporting that prior depression raises the risk of 415 developing IBS <sup>72,73</sup>. We found, however, no evidence for a causal effect of the genetic 416 417 liability of anxiety on IBS when accounting for correlated pleiotropy, in line with previous results <sup>18</sup>. Although the sample size for anxiety was more limited and these 418 419 results may also reflect lack of statistical power. Long term follow-up studies as well as 420 larger datasets and sensitivity analyses are required to confirm the robustness of these 421 results and to better understand the temporal relationship between IBS and comorbid 422 mental conditions.

423

A major strength of our study is the substantial larger sample size compared with previous studies. By conducting meta-analysis of GWAS summary statistics for IBS and comorbid mental conditions with MTAG we increased the effective sample size from 486,601 in the original IBS dataset to 887,490 individuals and the number of IBS genome-wide significant loci from six in the single-trait analysis to 42. Thirty-eight of

them were novel for IBS and 11 were not associated with any of the mental conditions under study, which highlight that MTAG combining GWAS on IBS and mental conditions is a robust strategy to identify trait specific genetic associations. In addition, four of the previously six identified loci were also significant in the present study <sup>18</sup>. Even though two identified loci demonstrated less association here, their associations were still suggestive (P<5E-07) and in concordance in the direction of the effect with the original GWAS study on IBS, which supports validity of the findings across studies.

437 The study, however, should be considered in the context of some limitations: (i) We did 438 not account for phenotypic overlap and cannot discard that comorbid conditions may 439 have biased the observed results. Also, IBS is considered a highly heterogenous 440 disorder with pathophysiological differences observed among clinical subtypes, 441 between genders, and across age groups and geographic locations<sup>1</sup>. Accounting for 442 such factors may contribute to better characterize the disorder, capture its genetic 443 background and identify overlap with other comorbid disorders that may impact on IBS risk, prognosis and clinical outcome  $^{6}$ ; (ii) Despite the strong genetic correlation 444 445 between IBS and the three mental conditions under study, MiXeR was unable to assess 446 the genetic overlap between IBS, depression and anxiety probably due to the high 447 polygenicity and low SNP heritability estimates for these traits (0.083 and 0.099, 448 respectively) and the limited sample size of the original GWAS on anxiety. We cannot 449 discard, either, that due to lack of power we did not detect IBS signals previously 450 reported for anxiety in the original GWAS or evidence for anxiety increasing the risk 451 for IBS in the causality analyses; (iii) Combining GWAS that differ a great deal in power may lead to inflation of FDR, according to MTAG authors <sup>24</sup>. In this study we 452 combined GWAS with different sample sizes, however their mean chi-squared was 453

454 similar and accordingly the max-FDR estimated in our IBS analysis was 0.02, which 455 suggested no inflation of our results. Moreover, despite increasing considerably the 456 effective sample size for IBS through the addition of multiple mental conditions, a 457 number of outcomes were related with gastrointestinal-related phenotypes, which 458 further supports this approach.

459

In summary, we identified novel risk loci for the IBS, reveal new insights of its polygenic architecture and extended previous knowledge on the genetic overlap and causal relationships between IBS, neuroticism, depression and anxiety. Overall, we advance our understanding of the biological mechanisms underlying IBS, highlighted candidate genes related to brain development and function as well as transcriptional regulation and provide insight into the association between IBS and comorbid mental disorders.

467

#### 468 Abbreviations

469 ADHD: attention-deficit/hyperactivity disorder; AIC: Akaike Information Criterion; 470 ASD: autism spectrum disorders; ATC: Anatomical Therapeutic Chemical; CAUSE: 471 Causal Analysis Using Summary Effect estimates; IBS: irritable bowel syndrome; FDR: 472 false discovery rate; ELPD: expected log pointwise posterior density; FUMA: 473 Functional Mapping and Annotation of GWAS; GCTA: Genome-wide Complex Trait Analysis; GWAS: Genome-wide association study;  $h^2_{SNP}$ : SNP heritability; LDSC: 474 475 Linkage disequilibrium score regression; MAGMA: Generalized gene-set analysis of 476 GWAS data; MTAG: Multi-Trait Analysis of GWAS

477

#### 478 **Declarations**

# 479 Ethics approval and consent to participate

- 480 This article contains results derived from data from human participants collected by
- 481 several studies performed by previous studies. All participants gave informed consent in
- 482 all the corresponding original studies. Our study is based on the large-scale GWAS
- 483 datasets, and not the individual-level data. Hence, ethical approval was not applicable.
- 484

#### 485 **Consent for publication**

- 486 Not applicable.
- 487

### 488 Availability of data and material

489 All data used in the current study is publicly available. Summary statistics for IBS can 490 European **Bioinformatics** Institute GWAS be download from Catalog 491 (https://www.ebi.ac.uk/gwas/). Summary statistics for neuroticism can be downloaded 492 from https://ctg.cncr.nl/software/summary\_statistics/ and http://www.ccace.ed.ac.uk. 493 Summary statistics depression downloaded for be from can 494 https://datashare.ed.ac.uk/handle/10283/3203. Summary statistics for anxiety can be 495 downloaded from http://www.nealelab.is/uk-biobank. Genotype tissue expression 496 (GTEx v8) http://www.gtexportal.org/home/datasets. portal: BRAINEAC: 497 eOTL http://www.braineac.org. catalogue: https://www.ebi.ac.uk/eqtl/Methods/. 498 PsychENCODE: http://resource.psychencode.org. CommonMind Consortium 499 (CMC/CMC): https://www.synapse.org//#!Synapse:syn5585484. WEB-based GEne 500 SeT AnaLysis Toolkit (WebGestAlt): http://www.webgestalt.org. SNP heritability and genetic correlations: https://github.com/bulik/ldsc. MiXeR: 501 502 https://github.com/precimed/mixer. Conditional analysis:

503 <u>https://yanglab.westlake.edu.cn/software/gcta/#COJO</u>. Multi-Trait Analysis of GWAS

504	(MTAG):	<u>https://githu</u>	b.com/omeed-n	naghzian/mta	<u>.g).</u>	Fine-map	ping:
505	https://github.co	m/mulinlab/CA	USALdb-finem	<u>apping-pip.</u>	Functional	Mapping	and
506	Annotation of (	Genome-Wide	Association Stu	idies (FUMA	A): <u>https://</u>	/fuma.ctgla	<u>ıb.nl/</u> .
507	Partitioned herit	ability: <u>https://g</u>	ithub.com/bulik	/ldsc/wiki/Pa	artitioned-H	<u>eritability</u> .	MR-
508	Base database:	https://github.	com/MRCIEU/1	nrbase_cases	studies. C	Causal An	alysis
509	Using	Summary	Effect	esti	mates	(CAU	JSE):
510	https://jean997.g	github.io/cause/p	oipeline.html.	The use of ea	ach software	e tools has	been
511	described in the	Methods section	n. Analysis code	e and scripts	used in the c	current stuc	ly are
512	available upon re	equest from the	corresponding a	authors.			

513

## 514 **Competing interests**

515 JARQ was on the speakers bureau and/or acted as consultant for Janssen-Cilag, 516 Novartis, Shire, Takeda, Bial, Shionogi, Sincrolab, Novartis, BMS, Medice, 517 Technofarma, Rubió and Raffo in the last 3 years. He also received travel awards (air 518 tickets + hotel) for taking part in psychiatric meetings from Janssen-Cilag, Rubió, Shire, 519 Takeda, Shionogi, Bial and Medice. The Department of Mental Health chaired by him 520 received unrestricted educational and research support from the following companies in 521 the last 3 years: Janssen- Cilag, Shire, Oryzon, Roche, Psious, and Rubió. ARU was on 522 the speakers bureau and/or acted as consultant for Janssen-Cilag and Organon in tha last 523 two years. All other authors declare no biomedical financial interests or conflicts of 524 interest. JS has served as consultant for Noventure SL, Devintecpharma, Aboca, 525 Reckitt, Ipsen & Pileje and discloses present and past recent scientific collaborations 526 with Salvat, Norgine, Alfa-Sigma, Cosmo, Adare, Ordesa and Danone that do not 527 constitute a conflict of interest in developing the content of the present manuscript. MS 528 was on the speakers bureau and/or acted as consultant/advisory Board member for

Tillotts, Menarini, Kyowa Kirin, Takeda, Biocodex, AlfaSigma, Sanofi, Janssen
Immunology, Pfizer, Ferrer, BioGaia, Falk Foundation, Danone Nutricia Research,
Ironwood, Genetic Analysis AS, DSM, Arena, Adnovate and Pharmanovia. He also
was funded by Glycom/DSM research grants.

533

### 534 Funding

535 This work was supported by the Agència de Gestió d'Ajuts Universitaris i de Recerca 536 (AGAUR, 2017SGR-00444 and 2017SGR-1461); the Ministry of Science, Innovation 537 and Universities (RYC2021-031324-I to J.C.D), the Instituto de Salud Carlos III 538 (CP22/00128 to M.S.A and CP22/00026 to S.A) and the European Regional 539 Development Fund (ERDF), the European Union H2020 Programme (H2020/2014-2020) under grant agreements no. 848228 (DISCOvERIE). This document is also an 540 541 output of a project grant (Grant Agreement nº: 848228, DISCOVERIE) funded under 542 H2020 Research Programme of the European Commission. The content of this 543 document represents the views of the author(s) only and is his/her/their sole 544 responsibility; it cannot be considered to reflect the views of the European Commission 545 or any other body of the European Union. The European Commission do not accept any 546 responsibility for use that may be made of the information it contains.

547

### 548 Authors' contributions

549 SA, MSA, JC, LVR, NLL and MR designed and supervised the study. SA analyzed the 550 data. SA, MSA, JC and MR wrote the manuscript draft. All authors contributed to the 551 interpretation of results and critically reviewed the manuscript.

# 552 **Bibliography**

- Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin
   Epidemiol 2014;6:71-80. http://dx.doi.org/10.2147/CLEP.S40245.
- 555 2. Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide Prevalence and
  556 Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation
- 557 Global Study. Gastroenterology 2021;160:99-114.e3.
- 3. Yeh H-W, Chien W-C, Chung C-H, et al. Risk of psychiatric disorders in irritable
  bowel syndrome-A nationwide, population-based, cohort study. Int J Clin Pract
  2018;72:e13212.
- Ford AC, Moayyedi P, Chey WD, et al. American College of Gastroenterology
   Monograph on Management of Irritable Bowel Syndrome. Am J Gastroenterol
   2018;113:1-18.
- 5. Zamani M, Alizadeh-Tabari S, Zamani V. Systematic review with meta-analysis:
  the prevalence of anxiety and depression in patients with irritable bowel
  syndrome. Aliment Pharmacol Ther 2019;50:132-143.
- 567 6. Lee S, Wu J, Ma YL, et al. Irritable bowel syndrome is strongly associated with
  568 generalized anxiety disorder: a community study. Aliment Pharmacol Ther
  569 2009;30:643-651.
- 570 7. Lee C, Doo E, Choi JM, et al. The Increased Level of Depression and Anxiety in
  571 Irritable Bowel Syndrome Patients Compared with Healthy Controls: Systematic
  572 Review and Meta-analysis. J Neurogastroenterol Motil 2017;23:349.
- Fond G, Loundou A, Hamdani N, et al. Anxiety and depression comorbidities in
  irritable bowel syndrome (IBS): a systematic review and meta-analysis. Eur Arch
  Psychiatry Clin Neurosci 2014;264:651-660.
- 576 9. Zhang QE, Wang F, Geng Q, et al. Depressive symptoms in patients with

|--|

- 578 2018;14:1504-1512.
- Hazlett-Stevens H, Craske MG, Mayer EA, et al. Prevalence of irritable bowel
  syndrome among university students: The roles of worry, neuroticism, anxiety
  sensitivity and visceral anxiety. J Psychosom Res 2003;55:501-505.
- Lydiard RB. Irritable bowel syndrome, anxiety, and depression: what are the
  links? J Clin Psychiatry 2001;62 Suppl 8:38-45; discussion 46-7.
- Nisticò V, Rossi RE, D'Arrigo AM, et al. Functional Neuroimaging in Irritable
  Bowel Syndrome: A Systematic Review Highlights Common Brain Alterations
  With Functional Movement Disorders. J Neurogastroenterol Motil 2022;28:185203.
- 588 13. Saffouri GB, Shields-Cutler RR, Chen J, et al. Small intestinal microbial
  589 dysbiosis underlies symptoms associated with functional gastrointestinal
  590 disorders. Nat Commun 2019;10.
- 591 14. Aguilera-Lizarraga J, Hussein H, Boeckxstaens GE. Immune activation in
  592 irritable bowel syndrome: what is the evidence? Nat Rev Immunol 2022.
- 593 15. Ford AC, Sperber AD, Corsetti M, et al. Irritable bowel syndrome. Lancet
  594 2020;396:1675-1688.
- 595 http://www.thelancet.com/article/S0140673620315488/fulltext.
- 596 16. Smoller JW. The Genetics of Stress-Related Disorders: PTSD, Depression, and
  597 Anxiety Disorders. Neuropsychopharmacology 2016;41:297-319.
- 598 17. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression:
  599 review and meta-analysis. Am J Psychiatry 2000;157:1552-1562.
- Eijsbouts C, Zheng T, Kennedy NA, et al. Genome-wide analysis of 53,400
  people with irritable bowel syndrome highlights shared genetic pathways with

mood and anxiety disorders. Nat Genet 2021;53:1543-1552.

- 603 19. Wu Y, Murray GK, Byrne EM, et al. GWAS of peptic ulcer disease implicates
- Helicobacter pylori infection, other gastrointestinal disorders and depression. Nat
  Commun 2021;12:1146.
- Nagel M, Jansen PR, Stringer S, et al. Meta-analysis of genome-wide association
  studies for neuroticism in 449,484 individuals identifies novel genetic loci and
  pathways. Nat Genet 2018;50:920-927.
- Howard DM, Adams MJ, Clarke TK, et al. Genome-wide meta-analysis of
  depression identifies 102 independent variants and highlights the importance of
  the prefrontal brain regions. Nat Neurosci 2019;22:343-352.
- 612 22. Bulik-Sullivan BK, Loh P-R, Finucane HK, et al. LD Score regression
  613 distinguishes confounding from polygenicity in genome-wide association studies.
  614 Nat Genet 2015;47:291-295.
- 615 23. Frei O, Holland D, Smeland OB, et al. Bivariate causal mixture model quantifies
  616 polygenic overlap between complex traits beyond genetic correlation. Nat
  617 Commun 2019 101 2019;10:1-11.
- Turley P, Walters RK, Maghzian O, et al. Multi-trait analysis of genome-wide
  association summary statistics using MTAG. Nat Genet 2018;50:229-237.
- Maihofer AX, Choi KW, Coleman JRI, et al. Enhancing Discovery of Genetic
  Variants for Posttraumatic Stress Disorder Through Integration of Quantitative
  Phenotypes and Trauma Exposure Information. Biol Psychiatry 2022;91:626636.
- 624 26. Yang J, Ferreira T, Morris AP, et al. Conditional and joint multiple-SNP analysis
  625 of GWAS summary statistics identifies additional variants influencing complex
  626 traits. Nat Genet 2012;44:369-375, S1-3.

- 627 27. Benner C, Spencer CCA, Havulinna AS, et al. FINEMAP: efficient variable
  628 selection using summary data from genome-wide association studies.
  629 Bioinformatics 2016;32:1493-1501.
- 630 28. Greenbaum J, Deng HW. A Statistical Approach to Fine Mapping for the
  631 Identification of Potential Causal Variants Related to Bone Mineral Density. J
  632 Bone Miner Res 2017;32:1651-1658.
- 633 29. Chen W, Larrabee BR, Ovsyannikova IG, et al. Fine Mapping Causal Variants
  634 with an Approximate Bayesian Method Using Marginal Test Statistics. Genetics
  635 2015;200:719-736.
- 30. Wang J, Huang D, Zhou Y, et al. CAUSALdb: a database for disease/trait causal
  variants identified using summary statistics of genome-wide association studies.
  Nucleic Acids Res 2020;48:D807-D816.
- 639 31. Watanabe K, Taskesen E, Van Bochoven A, et al. Functional mapping and
  640 annotation of genetic associations with FUMA. Nat Commun 2017;8:1826.
- 641 32. de Leeuw CA, Mooij JM, Heskes T, et al. MAGMA: Generalized Gene-Set
  642 Analysis of GWAS Data. PLoS Comput Biol 2015;11:e1004219.
- 643 33. Liao Y, Wang J, Jaehnig EJ, et al. WebGestalt 2019: gene set analysis toolkit
  644 with revamped UIs and APIs. Nucleic Acids Res 2019;47:W199-W205.
- 645 34. Finucane HK, Bulik-Sullivan B, Gusev A, et al. Partitioning heritability by
  646 functional annotation using genome-wide association summary statistics. Nat
  647 Genet 2015;47.
- 648 35. Hemani G, Zheng J, Elsworth B, et al. The MR-base platform supports
  649 systematic causal inference across the human phenome. Elife 2018;7:e34408.
- 650 36. Morrison J, Knoblauch N, Marcus JH, et al. Mendelian randomization accounting
  651 for correlated and uncorrelated pleiotropic effects using genome-wide summary

652 statistics. Nat Genet 2020;52:740-747.

- 653 37. Nagel M, Jansen PR, Stringer S, et al. Meta-analysis of genome-wide association
- 654 studies for neuroticism in 449,484 individuals identifies novel genetic loci and 655 pathways. Nat Genet 2018 507 2018;50:920-927.
- 656 38. Luciano M, Hagenaars SP, Davies G, et al. Association analysis in over 329,000
  657 individuals identifies 116 independent variants influencing neuroticism. Nat
- 658 Genet 2018;50:6-11.
- Anttila V, Bulik-Sullivan B, Finucane HK, et al. Analysis of shared heritability in
  common disorders of the brain. Science 2018;360.
- 40. Boutwell B, Hinds D, Agee M, et al. Replication and characterization of CADM2
  and MSRA genes on human behavior. Heliyon 2017;3.
- 41. Lüthi A, Laurent JP, Figurovt A, et al. Hippocampal long-term potentiation and
  neural cell adhesion molecules L1 and NCAM. Nature 1994;372:777-779.
- 42. Downer EJ, Cowley TR, Lyons A, et al. A novel anti-inflammatory role of
  NCAM-derived mimetic peptide, FGL. Neurobiol Aging 2010;31:118-128.
- 43. Turner CA, Lyons DM, Buckmaster CL, et al. Neural cell adhesion molecule
- peptide mimetics modulate emotionality: pharmacokinetic and behavioral studies
  in rats and non-human primates. Neuropsychopharmacol 2018 442 2018;44:356363.
- 44. Fregeau B, Kim BJ, Hernández-García A, et al. De Novo Mutations of RERE
  Cause a Genetic Syndrome with Features that Overlap Those Associated with
  Proximal 1p36 Deletions. Am J Hum Genet 2016;98:963.
- 45. Jordan VK, Fregeau B, Ge X, et al. Genotype–phenotype correlations in
  individuals with pathogenic RERE variants. Hum Mutat 2018;39:666.
- 676 46. Wray NR, Ripke S, Mattheisen M, et al. Genome-wide association analyses

677 identify 44 risk variants and refine the genetic architecture of major depression.

- 678 Nat Genet 2018 505 2018;50:668-681.
- 47. Mbarek H, Milaneschi Y, Hottenga JJ, et al. Genome-Wide Significance for
  PCLO as a Gene for Major Depressive Disorder. Twin Res Hum Genet
  2017;20:267-270.
- 48. Hyde CL, Nagle MW, Tian C, et al. Identification of 15 genetic loci associated
  with risk of major depression in individuals of European descent. Nat Genet
  2016;48:1031-1036.
- 49. Lee PH, Anttila V, Won H, et al. Genomic Relationships, Novel Loci, and
  Pleiotropic Mechanisms across Eight Psychiatric Disorders. Cell 2019;179:14691482.e11.
- 688 50. Ayano G. Dopamine: Receptors, Functions, Synthesis, Pathways, Locations and
  689 Mental Disorders: Review of Literatures. J Ment Disord Treat 2016;2.
- Kurnik-łucka M, Pasieka P, Łączak P, et al. Gastrointestinal dopamine in
  inflammatory bowel diseases: A systematic review. Int J Mol Sci 2021;22.
- 52. Tolstanova G, Deng X, Ahluwalia A, et al. Role of Dopamine and D2 Dopamine
  Receptor in the Pathogenesis of Inflammatory Bowel Disease. Dig Dis Sci
  2015;60:2963-2975.
- 695 53. Beck HC, Nielsen EC, Matthiesen R, et al. Quantitative proteomic analysis of
  696 post-translational modifications of human histones. Mol Cell Proteomics
  697 2006;5:1314-1325.
- 698 54. Aguirre JE, Winston JH, Sarna SK. Neonatal immune challenge followed by
  699 adult immune challenge induces epigenetic-susceptibility to aggravated visceral
  700 hypersensitivity. Neurogastroenterol Motil 2017;29:e13081.
- 701 55. Moloney RD, Stilling RM, Dinan TG, et al. Early-life stress-induced visceral

- 702 hypersensitivity and anxiety behavior is reversed by histone deacetylase
- inhibition. Neurogastroenterol Motil 2015;27:1831-1836.
- Vicario M, Martínez C, Santos J. Role of microRNA in IBS with increased gut
  permeability. Gut 2010;59:710-712.
- Martínez C, Rodinõ-Janeiro BK, Lobo B, et al. Original article: miR-16 and miR125b are involved in barrier function dysregulation through the modulation of
  claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea. Gut
  2017;66:1537.
- 2017,00.1237.
- 710 58. Wohlfarth C, Schmitteckert S, Härtle JD, et al. miR-16 and miR-103 impact 5-
- HT4 receptor signalling and correlate with symptom profile in irritable bowel
  syndrome. Sci Rep 2017;7:19.
- 59. Hong S, Zheng G, Wiley JW. Epigenetic regulation of genes that modulate
  chronic stress-induced visceral pain in the peripheral nervous system.
  Gastroenterology 2015;148:148-157.e7.
- 716 60. Tran L, Schulkin J, Ligon CO, et al. Epigenetic modulation of chronic anxiety
  717 and pain by histone deacetylation. Mol Psychiatry 2015;20:1219-1231.
- 718 61. Staudacher HM, Mikocka-Walus A, Ford AC. Common mental disorders in
- irritable bowel syndrome: pathophysiology, management, and considerations for
  future randomised controlled trials. Lancet Gastroenterol Hepatol 2021;6:401410.
- 62. Carabotti M, Scirocco A, Maselli MA, et al. The gut-brain axis: interactions
  between enteric microbiota, central and enteric nervous systems. Ann
  Gastroenterol Q Publ Hell Soc Gastroenterol 2015;28:203.
- Fadgyas-Stanculete M, Buga A-M, Popa-Wagner A, et al. The relationship
  between irritable bowel syndrome and psychiatric disorders: from molecular

- 727 changes to clinical manifestations. J Mol Psychiatry 2014;2.
- 728 64. Evrensel A, Ceylan ME. The Gut-Brain Axis: The Missing Link in Depression.
- 729 Clin Psychopharmacol Neurosci 2015;13:239-244.
- 730 65. Smriga M, Torii K. L-Lysine acts like a partial serotonin receptor 4 antagonist 731 and inhibits serotonin-mediated intestinal pathologies and anxiety in rats. Proc
- 732 Natl Acad Sci U S A 2003;100:15370-15375.

744

- 733 66. Bharucha AE, Zinsmeister AR, Camilleri M, et al. Effects of a serotonin 5-HT4 734 receptor antagonist SB-207266 on gastrointestinal motor and sensory function in 735 humans. Gut 2000;47:667-674.
- 736 67. Tam FS-., Hillier K, Bunce KT. Characterization of the 5-hydroxytryptamine 737 receptor type involved in inhibition of spontaneous activity of human isolated 738 colonic circular muscle. Br J Pharmacol 1994;113:143-150.
- 739 68. Papakostas GI, Mischoulon D, Shyu I, et al. S-adenosyl methionine (SAMe) 740 augmentation of serotonin reuptake inhibitors for antidepressant nonresponders 741 with major depressive disorder: A double-blind, randomized clinical trial. Am J 742 Psychiatry 2010;167:942-948.
- 743 Sharma A, Gerbarg P, Bottiglieri T, et al. S-adenosylmethionine (SAMe) for 69.
- neuropsychiatric disorders: A clinician-oriented review of research. J Clin 745 2017;78:e656-e667. https://pubmed.ncbi.nlm.nih.gov/28682528/. Psychiatry 746 Accessed May 18, 2022.
- 747 70. Moreau B, Clement P, Theoret Y, et al. Allopurinol in combination with 748 thiopurine induces mucosal healing and improves clinical and metabolic 749 outcomes in IBD. Therap Adv Gastroenterol 2017;10:819-827.
- 750 71. Lee YT, Hu LY, Shen CC, et al. Risk of psychiatric disorders following irritable 751 bowel syndrome: A nationwide population-based cohort study. PLoS One

# 752 2015;10:e0133283.

- 753 72. Sibelli A, Chalder T, Everitt H, et al. A systematic review with meta-analysis of
- the role of anxiety and depression in irritable bowel syndrome onset. Psychol
- 755 Med 2016;46:3065-3080.
- 756 73. Goodwin L, White PD, Hotopf M, et al. Life course study of the etiology of self-
- reported irritable bowel syndrome in the 1958 British birth cohort. Psychosom
- 758 Med 2013;75:202-210.
- 759
- 760
- 761
- 762

### 763 Figure legends

764

765 Figure 1. MTAG results of IBS and overlap with previous GWAS on IBS, 766 neuroticism, depression and anxiety. a) Z-scores of MTAG-IBS and original GWAS 767 on IBS, neuroticism, depression and anxiety for each of the independent lead SNPs 768 (n=42) found in MTAG-IBS results. Dotted grey line indicates 0 Z-score and solid grey 769 lines indicate statistical significance at P<5-E08. b) Manhattan plot of the MTAG-IBS 770 results. Dotted grey line indicates statistical significance at P<5-E08. c) QQ plot of the 771 MTAG-IBS results. d) Venn diagram depicting overlap among MTAG-IBS independent 772 lead SNPs and genome-wide significant hits in the original GWAS.

773

774 Figure 2. Follow-up analysis of MTAG-IBS results and causal analysis. a) 775 Functional annotation of the credible variants associated with MTAG-IBS. b) 776 RegulomeDB scores of the credible variants associated with MTAG-IBS. Low scores 777 indicate increasing likelihood of having regulatory function. c) Distribution of the 778 credible variants associated with MTAG-IBS across 15 categories of minimum 779 chromatin state. Lower state indicating higher accessibility and states from 1 to 7 refer 780 to open chromatin states. d) Genetic correlations (rg) between MTAG-IBS results and 781 17 phenotypes involving digestive, immunological and psychiatric disorders. Only 782 significant correlations after Bonferroni correction are displayed. e) Bar graphs 783 depicting the size of the genomic locus (left), number of candidate SNPs in the locus 784 (center) and number of mapped genes in the genomic locus (right). Genomic loci are 785 displayed by "chromosome: start position-end position". f) Partitioning of the SNP 786 heritability of the MTAG-IBS results using LD Score regression. Enrichment was 787 calculated by dividing the partial heritability of a category by the proportion of SNPs in

- 788 that category (proportion indicated by color). Only significant enrichments are
- displayed. g) Causal relationships between IBS and neuroticism, depression and anxiety
- 790 assessed using Causal Analysis Using Summary Effect estimates (CAUSE). Only
- associations with evidence of causal relationship are displayed.

Phenotype	N cases	N controls	N total	N effective <sup>a</sup>	GWAS Hits <sup>b</sup>	Reference
IBS	53,400	433,201	486,601	190,159	6	18
Neuroticism	-	-	□390,278 <sup>c</sup>	□390,278	136 <sup>d</sup>	20
Depression	170,756	329,443	500,199 °	449,856	102 <sup>d</sup>	21
Anxiety nerves or GAD	16,730	101,021	117,751	57,412	1	UKBB phenotype code: 20544_15

Table 1. Summary of the GWAS datasets used in the current study.

NOTE: GAD generalized anxiety disorder; UKBB UK Biobank.

<sup>a</sup> N effective sample sizes were calculated following the equation: Neff=4/(1/Ncases+1/Ncontrols).

<sup>b</sup> Number of genome-wide significant independent loci.

<sup>c</sup> Sample size excluding the 23andMe cohort.

<sup>d</sup> Hits including the 23andMe cohort.

Trait 1	Trait 2	Genetic	SF	7	P-vəlue	Intercent (SF)	Trait 1	Trait 2
11411 1	11 alt 2	Correlation	5E	L	1 -value	Intercept (SE)	$h^2$ (SE)	$h^2$ (SE)
IBS	Neuroticism	0.526	0.027	19.298	5.54E-83	1.013 (0.013)	0.069 (0.004)	0.146 (0.005)
IBS	Depression	0.587	0.026	22.714	3.23E-114	0.992 (0.01)	0.069 (0.004)	0.099 (0.004)
IBS	Anxiety	0.677	0.065	10.360	3.75E-25	0.999 (0.74)	0.068 (0.004)	0.083 (0.011)

Table 2. Genetic correlation estimates for IBS and neuroticism, depression and anxiety using Linkage Disequilibrium Score Regression (LDSC).

NOTE: SE, standard error;  $h^2$ , heritability.

					Cross-1	trait ana	lysis				Overlap	0 1 14	0 1		
Locus	Lead SNP	CHR	A1/A2	BP	Beta	SE	P	FRQ	Nearest Gene	Functional category	with original GWAS IBS	Overlap with previous GWAs on psychiatric traits	Overlap with previous GWAs	CADD	RDB
1	rs301806	1	T/C	8482078	-0,009	0.002	1.67E-09	0.58	RERE	intronic	NO	Neuroticism	Known	0.117	4 III rigt
2	rs11206127	1	A/G	53713549	-0.009	0.002	1.42E-08	0.43	LRP8	intronic	NO	No	Novel	0.128	6 fe
3	rs12755507	1	T/C	176164865	0.01	0.002	8.03E-10	0.625	RFWD2	intronic	NO	Depression	Known	6.038	4 Ve
4	rs113198479	1	A/G	191347803	-0.02	0.004	2.48E-08	0.953	RP11- 309H21.2	intergenic	NO	No	Novel	1.241	d. No reu: 6
5	rs72740550	1	A/G	197342380	-0.011	0.002	6.02E-09	0.219	CRB1	intronic	NO	Neuroticism & depression	Known	5.063	se allowed
6	rs115962846	2	A/G	58967058	-0.015	0.003	3.68E-08	0.912	LINC01122	ncRNA_intr onic	NO	Neuroticism	Known	2.103	d without 7
7	rs28496790	2	A/C	161950047	0.01	0.002	3.70E-09	0.708	AC009313.1	intergenic	NO	No	Novel	6.027	5 perm
8	rs138218528	2	T/C	212676884	0.009	0.002	2.84E-08	0.667	ERBB4	intronic	NO	Neuroticism & depression	Known	8.481	6 f
9	rs62246276	3	T/G	9445173	-0.011	0.002	2.28E-08	0.179	SETD5	intronic	NO	No	Novel	1.944	5
10	rs67416405	3	T/C	85539234	-0.009	0.002	8.27E-09	0.353	CADM2	intronic	YES	No	Known	3.769	6
11	rs1729951	3	T/G	136500733	-0.009	0.002	9.01E-09	0.389	RP11- 102M11.2	intergenic	NO	Neuroticism	Known	0.078	NA

Table 3. Results for the 42 independent lead SNPs identified in the MTAG-IBS analysis.

12	rs1442129	4	A/G	90849446	-0.009	0.002	1.22E-08	0.453	MMRNI	intronic	NO	No	Novel	5.378	NA
13	rs77087420	4	A/G	123122856	0.018	0.003	2.64E-08	0.945	KIAA1109	intronic	NO	No	Novel	4.579	7
14	rs12513440	5	A/G	7259853	0.01	0.002	2.73E-08	0.243	RP11-404K5.3	intergenic	NO	No	Novel	0.327	5
15	rs3099439	5	T/C	87545318	-0.011	0.002	1.14E-12	0.539	TMEM161B	intronic	NO	Depression	Known	1.562	NA
16	rs4481363	5	A/C	164474719	0.009	0.001	1.01E-09	0.524	CTC-340A15.2	ncRNA_intr onic	NO	Neuroticism & depression	Known	6.522	6
16	rs180928232	5	A/G	166185949	-0.012	0.002	4.46E-08	0.149	CTB-7E3.1	intergenic	NO	Neuroticism	Known	2.692	6
17	rs200977	6	T/C	27854301	0.015	0.002	1.04E-11	0.873	HIST1H3J	intergenic	NO	Neuroticism & depression	Known	1.251	NA
17	rs2534664	6	A/G	31469591	0.01	0.002	2.63E-10	0.456	MICB	intronic	NO	Depression	Known	3.484	NA
17	rs1144708	6	T/C	31710020	-0.01	0.002	7.49E-10	0.357	MSH5:MSH5- SAPCD1	intronic	YES	No	Known	0.372	6 allo
18	rs12374612	6	T/C	100955752	0.009	0.001	1.02E-08	0.478	ASCC3	downstream	NO	Neuroticism	Known	0.29	6 6
19	rs2189246	7	A/G	82444372	0.01	0.001	1.98E-10	0.523	PCLO	intronic	NO	Depression	Known	1.139	7 0
20	rs6956352	7	A/G	109131367	0.009	0.002	1.64E-08	0.458	AC073071.1	intergenic	NO	Depression	Known	9.195	7
21	rs4726814	7	T/C	146691924	-001	0.002	1.30E-08	0.275	CNTNAP2	intronic	NO	No	Novel	1.37	7 50
22	rs4478545	8	A/G	94672542	-0.01	0.002	4.77E-09	0.285	LINC00535	ncRNA_intr onic	NO	No	Novel	1.326	6
23	rs3793577	9	A/G	23737627	-0.01	0.002	3.46E-10	0.463	ELAVL2	intronic	NO	Neuroticism	Known	19.76	5
24	rs4744242	9	T/G	96236711	-0.011	0.002	8.68E-13	0.336	FAM120A	intronic	YES	Neuroticism	Known	2.858	6
25	rs10123941	9	T/C	120518162	-0.01	0.002	3.96E-09	0.727	snoZ13_snr52	intergenic	NO	Neuroticism	Known	1.108	6

0	rs6584631	10	T/C	106656137	-0.01	0.002	7.23E-09	0.244	SORCS3	intronic	NO	Depression	Known	0.167	4
7	rs4937872	11	A/G	112827715	-0.012	0.002	7.15E-15	0.589	RP11- 629G13.1	intergenic	YES	Neuroticism	Known	0.044	e
3	rs9530139	13	T/C	31847324	-0.011	0.002	2.11E-08	0.194	B3GALTL	intronic	NO	Depression	Known	0.529	ŧ
)	rs9597797	13	T/G	59183795	-0.01	0.002	1.42E-09	0.251	CTAGE16P	intergenic	NO	Neuroticism	Known	0.278	7
)	rs2121708	14	A/G	42146572	-0.009	0.001	8.26E-10	0.517	LRFN5	intronic	NO	Depression	Known	0.043	1
1	rs35641442	14	A/G	75207263	0.009	0.002	6.65E-09	0.459	FCF1	intergenic	NO	Neuroticism & depression	Known	11.4	7
2	rs1862743	16	A/C	60743834	-0.009	0.001	1.08E-08	0.492	GNPATP	intergenic	NO	No	Novel	1.06	ŧ
3	rs2978362	18	T/C	32959397	-0.008	0.001	2.65E-08	0.527	ZNF396	intergenic	NO	Depression	Known	1.024	1
3	rs11877758	18	T/G	35138110	-0.012	0.002	1.28E-13	0.692	CELF4	intronic	NO	Neuroticism & depression	Known	2.718	7
4	rs17410557	18	T/C	50776391	-0.009	0.002	1.13E-08	0.606	DCC	intronic	NO	Neuroticism & depression	Known	4.502	7
4	rs12958048	18	A/G	53101598	0.01	0.002	4.76E-11	0.333	TCF4	intronic	NO	Neuroticism	Known	2.08	5
5	rs2111530	19	A/G	31891006	-0.009	0.002	9.47E-09	0.602	AC007796.1	ncRNA_intr onic	NO	No	Novel	17.04	7
5	rs2024568	20	T/C	44732089	0.011	0.002	1.52E-10	0.246	RPL13P2	intergenic	NO	Neuroticism & depression	Known	0.149	e
7	rs11090039	22	A/G	41496800	0.012	0.002	2.87E-13	0.284	EP300	intronic	NO	Neuroticism	Known	9.707	5
JTE 1not	E: CHR, chromo ation Dependent	bsome; 7 t Deplet	A1, effect	allele with re RDB, Regulor	spect to neDB sco	the Beta ore.	; A2, alterna	ate allele	; BP, base pair	position; SE, st	andard e	rror; FRQ, frequency	y of the A1;	CADD,	Con
														40	

Norelap with previous GWAS was examined by identifying hits within 1/-5000lkb in the MTAG-hits for IBS and original GWAS hits for each trait (i.e. neuroicitism, depression and analysis).

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

